Loading
Mimedx Group, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Capper Joseph H, was filed 05 May 2025.
Insider Decl.
336
Thresholds
n/a
Buy Volume
€3M
8 ops. · all time
Sell Volume
€13M
77 ops. · all time
Who traded when
BuySaleKimberly Maersk-Moller4 sales
William Frank Hulse IV3 sales
Joseph H. Capper1 buy
Ricci S. Whitlow1 sale
Since the insiders bought
- -44.6%Entry US$6.61 · Close at T+365 US$3.66
- +20.1%Entry US$7.66 · Close at T+365 US$9.20
- +79.1%Entry US$7.59 · Close at T+365 US$13.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Mimedx Group, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$7.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,823 of 26,248 companies
76.9
score / 100
Value81
Quality72
FCF yld13%
Earn yld8.9%
EV/EBITDA7.2x
ROE2.9%
Gross mgn83%
Net mgn12%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.74
Analyst consensus
5 analystsStrong buy
US$6.00Target US$7.40(+98%)US$8.00
Income statement
RevenueUS$418.6M
Gross profitUS$345.6M83% margin
EBITDAUS$78.8M19% margin
Net incomeUS$48.6M1.8% margin
Valuation
PER (trailing)93.5x
PER (forward)35.6x
P/Book2.5x
Beta1.17
Balance sheet & cash
Market capUS$545.8M
Total debtUS$18M
Free Cash FlowUS$73M
Debt / Equity8%
Profitability & ownership
ROE2.9%
ROA1.9%
% insiders2.1%
% institutions78.0%
Last declaration on 7 July 2026
Declarations336 total
12,749 shares@ US$3.950.0072% mcap3.8% of flowCommon StockSEC:0001376339-26-000057:0
19,820 sharesCommon StockSEC:0001376339-26-000054:0
50,913 sharesCommon StockSEC:0001376339-26-000049:0
6,762 shares@ US$4.383.7% of flowCommon StockSEC:0002029167-26-000006:0
20,245 shares@ US$4.382.2% of flowCommon StockSEC:0001796044-26-000009:0
96,363 shares@ US$4.5024.2% of flowCommon StockSEC:0001618861-26-000006:1
61,460 shares@ US$4.505.8% of flowCommon StockSEC:0001796044-26-000007:1
21,270 shares@ US$4.5010.5% of flowCommon StockSEC:0002029167-26-000004:1
42,845 shares@ US$4.5023.7% of flowCommon StockSEC:0002029167-26-000004:0
136,364 shares@ US$4.5014.9% of flowCommon StockSEC:0001796044-26-000007:0
243,000 shares@ US$4.5080.7% of flowCommon StockSEC:0001618861-26-000006:0
74,163 shares0Common StockSEC:0001798744-26-000006:0
74,987 shares0Common StockSEC:0001796044-26-000005:0
74,163 shares0Common StockSEC:0001618861-26-000004:0
74,163 shares0Common StockSEC:0002029167-26-000002:0
371,094 shares0Common StockSEC:0001456817-26-000006:0
61,961 shares@ US$5.1210.7% of flowCommon StockSEC:0001798744-26-000003:0
58,300 shares@ US$7.415653.6% of flowCommon StockSEC:0002029167-25-000008:0
12,749 shares@ US$6.345.9% of flowCommon StockSEC:0001376339-25-000080:0
12,034 shares@ US$5.968.8% of flowCommon StockSEC:0001376339-25-000077:0
28,609 sharesCommon StockSEC:0001376339-25-000075:0
28,609 shares@ US$6.4720.5% of flowCommon StockSEC:0001376339-25-000072:0
28,609 shares@ US$6.4745.5% of flowCommon StockSEC:0001376339-25-000064:0
28,609 shares@ US$6.4720.5% of flowCommon StockSEC:0001376339-25-000070:0
28,609 shares@ US$6.4720.5% of flowCommon StockSEC:0001376339-25-000068:0
25 of 336 declarations
About Mimedx Group, Inc.
At Mimedx Group, Inc., a US healthcare and pharma company listed on Nasdaq with a market capitalisation of USD 639.2 million, the heaviest sale comes from a shareholder: Okumus Fund Management Ltd., a holder of more than 10% of the shares, sold EUR 3,753,628 on January 23, 2019 and EUR 1,164,675 the day before. William Charles Taylor, President and COO, sold EUR 1,035,683 on June 14, 2017.
In total, 77 sales (72 with an amount) worth EUR 12.7 million, median EUR 48,092, face 8 purchases worth EUR 2.6 million, median EUR 243,291: 9% purchases among open-market trades. Purchases are few but large. Joseph H. Capper, Chief Executive Officer, bought EUR 1,122,472 on May 2, 2025 and EUR 334,982 on June 22, 2023; Parker H. Petit, Chairman & CEO, EUR 296,213 on May 12, 2016.
Read moreShow less
The 336 filings, published from February 24, 2016 to July 7, 2026 by 38 insiders, include 231 grants and 10 option exercises. Insiders hold 2.1% of the capital. William Frank Hulse IV, General Counsel and CAO, and William Charles Taylor filed 24 each. The year 2020 has 43, 2021 only 31. Over the last twelve months: 18 filings, of which 1 sale and no purchase.
